Neufeld Cardiac Research Institute, Tel Aviv University, Sheba Center for Regenerative Medicine, Stem Cells, and Tissue Engineering, and Tamman Cardiovascular Research Institute, Tel Aviv, Israel.
J Am Coll Cardiol. 2013 Nov 12;62(20):1890-901. doi: 10.1016/j.jacc.2013.07.057. Epub 2013 Aug 21.
This study sought to investigate the hypothesis that the favorable effects of mesenchymal stromal cells (MSCs) on infarct repair are mediated by macrophages.
The favorable effects of MSC therapy in myocardial infarction (MI) are complex and not fully understood.
We induced MI in mice and allocated them to bone marrow MSCs, mononuclear cells, or saline injection into the infarct, with and without early (4 h before MI) and late (3 days after MI) macrophage depletion. We then analyzed macrophage phenotype in the infarcted heart by flow cytometry and macrophage secretome in vitro. Left ventricular remodeling and global and regional function were assessed by echocardiography and speckle-tracking based strain imaging.
The MSC therapy significantly increased the percentage of reparative M2 macrophages (F4/80(+)CD206(+)) in the infarcted myocardium, compared with mononuclear- and saline-treated hearts, 3 and 4 days after MI. Macrophage cytokine secretion, relevant to infarct healing and repair, was significantly increased after MSC therapy, or incubation with MSCs or MSC supernatant. Significantly, with and without MSC therapy, transient macrophage depletion increased mortality 30 days after MI. Furthermore, early macrophage depletion produced the greatest negative effect on infarct size and left ventricular remodeling and function, as well as a significant incidence of left ventricular thrombus formation. These deleterious effects were attenuated with macrophage restoration and MSC therapy.
Some of the protective effects of MSCs on infarct repair are mediated by macrophages, which are essential for early healing and repair. Thus, targeting macrophages could be a novel strategy to improve infarct healing and repair.
本研究旨在验证这样一个假设,即间充质基质细胞(MSCs)对梗死修复的有益作用是通过巨噬细胞介导的。
MSC 治疗心肌梗死(MI)的有益作用是复杂的,尚未完全了解。
我们在小鼠中诱导 MI,并将其分配到骨髓 MSC、单核细胞或盐水注射到梗死部位,同时进行早期(MI 前 4 小时)和晚期(MI 后 3 天)巨噬细胞耗竭。然后,我们通过流式细胞术分析梗死心脏中的巨噬细胞表型,并通过体外巨噬细胞分泌组学分析巨噬细胞分泌组学。通过超声心动图和斑点跟踪应变成像评估左心室重构和整体及局部功能。
与单核细胞和盐水处理的心脏相比,MSC 治疗在 MI 后 3 天和 4 天显着增加了梗死心肌中修复性 M2 巨噬细胞(F4/80(+)CD206(+))的百分比。MSC 治疗或与 MSC 孵育或 MSC 上清液孵育后,与梗死愈合和修复相关的巨噬细胞细胞因子分泌显着增加。重要的是,无论是否进行 MSC 治疗,早期巨噬细胞耗竭都会使 MI 后 30 天的死亡率增加 30%。此外,早期巨噬细胞耗竭对梗死面积和左心室重构和功能产生最大的负面影响,并导致左心室血栓形成的发生率显着增加。这些有害影响通过巨噬细胞恢复和 MSC 治疗得到减轻。
MSC 对梗死修复的一些保护作用是通过巨噬细胞介导的,巨噬细胞对于早期愈合和修复是必不可少的。因此,靶向巨噬细胞可能是改善梗死愈合和修复的一种新策略。